Agoracom Blog Home

Posts Tagged ‘tsx-v’

Kiaro, One Of Canada’s Largest Cannabis Retailers, To Leverage The Power Of Fobi Real-time Artificial Intelligence To Transform Their Approach To Cannabis Retail

Posted by AGORACOM-JC at 5:46 PM on Wednesday, September 29th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

“I was blown away by FOBI “  ($KO CEO Daniel Petrov)

“Kiaro has built an amazing tech driven cannabis retail business”  ($FOBI CEO Rob Anson)

If you’re a shareholder of one of these companies, here is what you need to know about each that makes this technology partnership so powerful:

KIARO is one of Canada’s largest retailers of cannabis, with 16 locations and forecasted annual revenue of $42.7 million from these locations, at a gross profit of $13.7M with further growth anticipated.

FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space.  From that core technology they have built a technology stack on top of it that is second to none.

More than just talk, FOBI has completes Integrations with Lightspeed and Shopify to provide real-time Point of Sale data analytics.  Moreover, they recently announced another $250.000 Data Consulting Agreement with Azincourt Energy

TOGETHER they combined forces in this press release “Fobi Signs $240,000 Data Consulting Agreement With Kiaro Holdings, A National Cannabis Retailer With 16 Locations And Forecasted Annual Revenue Of $42.7 Million, To Assist With Development Of Data Warehouse”

How important is this agreement to each other’s success? 


Watch this powerful interview with FOBI CEO, Rob Anson and Kiaro CEO Daniel Petrov to find out exactly.

VIDEO – With $17M In Profitable Cannabis Revenues Already, The Latest Kiaro Acquisitions Are Expected To Create $43M In Revenue & $13.7M Gross Profit

Posted by AGORACOM-JC at 4:54 PM on Friday, July 16th, 2021
Kiaro holdings corp  kiaro completes kelowna cannabis retail loc

Kiaro Holdings is an multi-channel cannabis retailer and distributor with existing storefronts across British Columbia , Saskatchewan and Ontario, a wholesale distribution servicing Saskatchewan and ecommerce sites in Canada , the US and Australia, which have resulted in the following:

  • ANNUAL REVENUE              $17.1M Up 230%
  • ANNUAL GROSS PROFIT     $5.1M Up 281%  
  • Q1 REVENUE                          $5.2M Up 94%
  • Q1 GROSS PROFIT                 $1.56M Up 118%

But CEO Daniel Petrov and his team of retail winners aren’t stopping there. On July 13th, $KO announced  Kiaro Acquires Hemisphere Cannabis and Adds 7 Retail and 2 Development Locations in Ontario To Become a Prominent National Cannabis Retailer with Forecasted Annual Revenues of $42.7 Million.

If you believe in the long-term future of the cannabis market, then you have to discover KIARO by watching our first ever interview with CEO Daniel Petrov.

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

VIDEO – Cardiol Therapeutics $ $CRTPF is a Clinical-Stage Biotech Firm taking on the $30BN Heart Disease Healthcare Market via Cannabidiols and Cutting-Edge Anti-Inflammatory Therapies

Posted by AGORACOM-JC at 4:23 PM on Thursday, April 22nd, 2021

Cardiol Therapeutics $ $CRTPF is a groundbreaking, clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in treating hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free.

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

The company is also developing proprietary cannabidiol formulations for the treatment of chronic heart failure.

One such key development is its commercial product, Cortalex™, an extra-strength formulation (100 mg/mL concentration) of cannabidiol oil that is pharmaceutically produced to be free of THC. Cardiol believes Cortalex™ to be the purest form of cannabidiol oil available in Canada.

It is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Canada’s largest pharmacy retailer, Shoppers Drugs Mart.

  • In March 2020, Cardiol signed a supplier agreement to become a medical cannabidiol supplier to Shoppers Drug Mart. The retailer will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for sale in all provinces and territories in Canada through Shoppers’ online store, Medical Cannabis by Shoppers.

And there’s plenty more to write home about:

  • ~ $27M from exercise of warrants + equity raise since June 2020
  • Uplisting to NASDAQ
  • Team expansion with Chief Medical Officer hire

David Elsley, Cardiol Therapeutics’ President & CEO, gives us the low-down. Check it out:

Fabled Silver Gold $ $FBSGF Amends and Restates Copper Option Agreements and Acquires Additional Claims $ $ $GMBXF $

Posted by AGORACOM-Eric at 8:18 AM on Thursday, April 8th, 2021
This image has an empty alt attribute; its file name is fabled-square.png

Fabled Silver Gold Corp. (“Fabled” or the “Company“) (TSXV:FCO)(OTCQB:FBSGF)(FSE:7NQ) is pleased to announce that it has entered into an amended and restated option agreement (the “Amended Agreement“) with respect to certain of the Company’s copper properties, being Neil Property and the Toro Property, located in the Liard Mining Division in northern British Columbia.

Pursuant to the Amended Agreement,Fabled also now has the right to acquire additional claims covering an additional 3,842 hectares located in the same mineral belt (together with the Neil Property and the Toro Property, the “Muskwa Property“) from High Range Exploration Ltd. (the “Optionor“).

Under the existing option agreements, the Company was required to pay to the Optionor $5,000,000 in cash or shares by August 17, 2021, and a further $5,000,000 in cash or shares by March 3, 2022 to acquire an additional 50% of Neil Property and Toro Property not already owned by Fabled. In addition, Fabled was required to pay an additional $200,000 per annum to the Vendor in advance royalty payments, and pay a 2% NSR on the commencement of commercial production. Prior to entering into the Amended Agreement, past and unpaid advance royalty payments of $750,000 were to become due on March 31, 2021. Such amounts are not due under the Amended Agreement.

Pursuant to the Amended Agreement, in consideration for the right to acquire the whole and expanded Muskwa Property Fabled has agreed pay to the Optionor, in cash:

(i) $200,000 on the closing date;

(ii) $500,000 on the date that is twelve months after the closing date;

(iii) $750,000 on the date that is twenty-four months after the closing date;

(iv) $1,000,000 on the date that is thirty-six months after the closing date; and

(v) $2,000,000 on the date that is forty-eight months after the closing date.

The Muskwa Property will be subject to a 2% NSR payable to the Optionor but no advance royalty payments will now be due.

The additional claims included in the Muskwa Property (which include the Bronson deposit and additional claims contiguous and to the north of the Neil Property and ChurchKey Property) increase the Company’s land package within the same mineral belt which is believed to be 6 miles wide and 40 miles long and that trends north 35 degrees west and contains the Davis-Keays Eagle Vein, the past-producing Churchill Copper Mine Magnum Vein, the Neil Vein, the Toro/Churchill, and Bronson deposits, each of which are now under option to Fabled.

Read More

Else $ $BABYF to launch product rollout to “Big Y” stores in April $ $ $ $

Posted by AGORACOM-JC at 8:03 AM on Wednesday, April 7th, 2021
  • Announced that it will begin its Northeast rollout by mid April 2021 , through “Big Y” World Class Markets, out of Springfield Massachusetts
  • Else’s Plant-Based Nutrition for Toddlers will be available for purchase in all 71 Big Y grocery stores.

VANCOUVER, BC , April 7, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company , announces that it will begin its Northeast rollout by mid April 2021 , through “Big Y” World Class Markets, out of Springfield Massachusetts . Else’s Plant-Based Nutrition for Toddlers will be available for purchase in all 71 Big Y grocery stores.

“Launching with Big Y represents another exciting milestone for Else,” said Hamutal Yitzhak , Else CEO and Co-Founder. “The northeast population size is paramount to the growth of our brand. Big Y’s large-format shelves and health-minded shoppers represent an opening into the progressive New England customer-base. We are eager to bring real, whole food-based, clean label solutions to families in this region,” she added.

About Big Y

Big Y is one of the largest independently owned supermarket chains in New England , and it employs over 12,000 people. In 2020 Big Y was the 210th-largest private company in the United States , according to that year’s Forbes magazine “500 Largest Private Companies” list. As of October 2020 , Big Y operates 71 supermarkets in Massachusetts and Connecticut ; [1] [3] many of which are located in the metropolitan areas of Springfield , Worcester , Greater Boston , and Hartford . In addition to its traditional supermarkets, Big Y owns and operates two specialty markets: Table & Vine, a large specialty liquor and wine store in West Springfield ; and the Fresh Acres Market, a concept mixing an open-air-style farmers’ market with upscale food choices, in Springfield . Big Y also operated two standalone pharmacies in Springfield and Wilbraham before eventually folding them into the pharmacies located in its nearby stores.

Loop Insights $MTRX $RACMF Finalizes API Integration with Vend POS, Vend to Launch Full Sales & Marketing Program to Its Global Retail Client List $ $ $SNSR $BSQR $

Posted by AGORACOM-JC at 8:00 AM on Wednesday, April 7th, 2021*f9msDHyceA_TbRM30jQhsw.png
  • Announced the Company has completed its integration to Vend’s Billing API, providing Vend retailers with seamless onboarding to Loop’s multi-domain, franchise compliance, and historical reporting solutions

VANCOUVER, British Columbia, April 07, 2021 — Loop Insights Inc. (MTRX:TSXV RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights and enhanced customer engagement to the brick and mortar space, is pleased to announce the Company has completed its integration to Vend’s Billing API, providing Vend retailers with seamless onboarding to Loop’s multi-domain, franchise compliance, and historical reporting solutions.

Loop Insights First to Integrate with Vend’s Billing API, Providing a Seamless Onboarding Option for Vend’s Global Client List of over 20,000 Customer Locations Worldwide

Vend Director of Product Partnerships Lowry Gladwell stated:
“The completion of Loop’s integration with the Vend Billing API is an example of how Vend works closely with partners to deliver value for our retailers. It has been great to see Loop’s enthusiasm for the project and we’re thrilled that our Vend retailers can now onboard clients to benefit from Loop’s products and services faster than ever before, giving them easier access to the multi-domain, franchise and historical reporting that Loop offers. Additionally, our announced acquisition by Lightspeed, which is expected to close towards the end of April, will allow Vend and Loop to reach new clients, with a particular focus on expansion in Asia-Pacific. I look forward to connecting Vend’s expanding customer base with Loop’s amazing solution stack.”

Loop Insights CEO Rob Anson stated: “Vend’s support of Loop’s integration to their Billing API speaks volumes about its confidence in Loop and our retail solutions. With the development of our Billing API integration now complete, both Loop and Vend are positioned to generate new sales opportunities through this successful partnership. Loop’s retail Insights service can now be onboarded to over 20,000 Vend customer locations, with the ability to scale to support Lightspeed’s 135,000 worldwide locations through Lightspeed’s recent acquisition of Vend. This API integration represents a massive revenue-generating opportunity for Loop, Vend, Lightspeed, and their many customers.”

Loop Insights is the first company to complete a full billing API integration with Vend, reflecting Vend’s confidence in Loop’s products and their ability to deliver value to Vend’s clients. Vend has introduced Loop to all of their customers worldwide through their digital customer newsletter and some Vend customers have already begun the onboarding process with Loop.  Vend is now expected to launch expanded sales and marketing campaigns in support of Loop and its API integration, explaining the benefits of Loop’s products and services to Vend’s growing customer list.

With Loop’s Insights, Engage, and Wallet pass platform all gaining interest from brands and retailers across the world, Vend will now be able to offer a simple onboarding process for retailers, drastically reducing the time required to integrate a new client and deploy Loop’s products and services.

On March 11th , Vend Director of Product Partnerships Lowry Gladwell joined the ‘Loop Experience’ podcast to discuss the benefits of Loop’s integration with the Vend API, particularly for franchisors looking to integrate multiple locations. Listen to the full episode here or read the full interview transcript here .

API Integration Will Accelerate Loop’s Growth in the $23-trillion Global Retail Market with Access to Over 155,000 Global Retail Clients

Loop Insights’ integration with the Vend Billing API will allow Loop to more rapidly onboard Vend’s growing client list in the $23-trillion global retail market .

On March 11th , Lightspeed POS Inc. (NYSE:LSPD) (TSX:LSPD), a leading provider of cloud-based, omnichannel commerce platforms, announced it had entered into a definitive agreement to acquire Vend. The acquisition will greatly expand Lightspeed’s existing foothold in Asia-Pacific, approximately doubling its existing customer base in that region.

The combination of Lightspeed’s scale with the talent and technology available to Vend, including Loop Insights’ products and services, is expected to greatly benefit Lightspeed and its massive customer base. Following the closing of the acquisition, Lightspeed will operate as the preferred technology provider for over 155,000 existing customer locations worldwide.

This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management

About Vend
Vend is a cloud-based point-of-sale and retail management software that lets retailers run their business in-store, online, and on-the-go. Vend includes inventory management, eCommerce integrations, customer loyalty, and reporting analytics tools. The first POS built for iOS, Vend is trusted by retailers in over 140 countries and is used in more than 20,000 customer locations worldwide. Vend integrates with leading tools like Bigcommerce, Quickbooks and Marsello and provides seamless integrated payment options by partnering with major banks and processors around the world. Founded in 2010, Vend has offices in Auckland, London, Toronto and Melbourne, and has raised more than $50 million from top-tier investors.  For more information, please visit:

About Loop Insights
Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative automated marketing and contactless payment solutions built on artificial intelligence (“AI”) to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.


POET Technologies $ $POETF to Participate at Upcoming Virtual Financial Conferences

Posted by AGORACOM-JC at 5:45 PM on Tuesday, April 6th, 2021
  • Cormark Securities’ 2021 Virtual Inflection Conference
    Power Technology Session – Date: Tuesday, April 13
  • OTC Virtual Technology Conference – Date: Thursday, April 15

TORONTO, April 06, 2021 — POET Technologies, Inc. (OTCQX: POETF; TSX Venture: PTK) the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and telecommunication markets, today announced that management is scheduled to present and host meetings with participating investors at the following virtual financial conferences.

Cormark Securities’ 2021 Virtual Inflection Conference
Power Technology Session
Date: Tuesday, April 13
Presentation: 11:30 AM Eastern Time
Presenters: Suresh Venkatesan, Chairman & CEO; Vivek Rajgarhia, President & General Manager and Thomas Mika, Executive Vice President & CFO

The Cormark Securities Conference is an investor-focused conference discussing how to invest in an age of sustainability and new technologies. POET will be participating in the Power Technology Session which will include meetings with institutional investors. Interested investors should contact their Cormark representative to register.

OTC Virtual Technology Conference
Date: Thursday, April 15
Presentation: 10:30 AM Eastern Time
Presenter: Thomas Mika, Executive Vice President & CFO

POET invites individual and institutional investors, as well as advisors and analysts, to attend the real‐time, interactive presentations on It is recommended that investors pre‐register and run the online system check to expedite participation and receive event updates by registering on the OTC event calendar website:

Additionally, POET’s presentation materials will be made available on the Presentations and Events page of the Company’s website.

Option Grants

At a regular meeting of the Board of Directors held on March 24, 2021, as part of the Company’s incentive stock option grant program, the Board approved the granting of a total of 4,831,250 options to be granted on April 6, 2021 to directors, employees and consultants of the Company to purchase common shares. The approved grant represents 1.4% of the total issued and outstanding common shares of the Company. The approved total included 731,250 stock options to non-management directors (0.21%), 2,050,000 to officers (0.6%), 2,000,000 to other employees (0.59%), and 50,000 to consultants (0.01%). 

The options are exercisable for 10 years at a price of C$1.19 being the closing price of the Company’s shares on April 5, 2021. The directors’ options vest quarterly in arrears over the one year of service as a director. All other options granted to employees vest 25% on the first anniversary of the grant and the balance vests quarterly over a further three-year period thereafter. The grant to the directors represents the option portion of directors’ fees for the 12-month period beginning April 1, 2021. The options granted to a consultant will vest based on certain performance milestones of the consultant over a 12-month period.

Read More:

PyroGenesis $PYR to Present at Zooming with LD on April 12th $RTN $NOC $UTX $ $

Posted by AGORACOM-JC at 8:21 AM on Tuesday, April 6th, 2021
  • Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, will be presenting at Zooming with LD on Monday April 12 th , 2021.

MONTREAL, April 06, 2021 — PyroGenesis Canada Inc. ( (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), (the “Company”, the “Corporation” or “PyroGenesis”) a Company that designs, develops, manufactures and commercializes plasma atomized metal powder, environmentally friendly plasma waste-to-energy systems and clean plasma torch products, is pleased to announce that, Mr. P. Peter Pascali, CEO and Chair of PyroGenesis, will be presenting at Zooming with LD on Monday April 12 th , 2021.

EventZooming with LD
DateApril 12 th , 2021
PresentationApril 12 th @ 11:00AM Eastern Time

About LD Micro  

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit 

In September 2020, LD Micro was acquired by SRAX, a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit and 

About PyroGenesis Canada Inc.  

PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m 2 and 2,940 m 2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at, or at Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the NASDAQ Stock Market, LLC accepts responsibility for the adequacy or accuracy of this press release.  

SOURCE PyroGenesis Canada Inc. 

For further information please contact:
Rodayna Kafal, Vice President, IR/Comms. and Strategic BD
Phone: (514) 937-0002, E-mail: [email protected]

Valeo Pharma $VPH $VPHIF Reports its First Quarter 2021 Results and Highlights $ $ $ $

Posted by AGORACOM-JC at 6:40 PM on Wednesday, March 31st, 2021
  • Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
  • Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
  • Frederic Fasano appointed as President and Chief Operating Officer
  • Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
  • Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study

MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .

“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.

Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.


  1. IQVIA CDH June 2020

First Quarter 2021 Financial Results and Highlights

  • Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
  • Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
  • Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .

First Quarter 2021 Business and Product Highlights

  • In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
  • In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
  • In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
  • In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
  • In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.

Subsequent Events

  • In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
  • In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;

Q1 2021 Webcast and Conference Call

Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via:

Financial Statements and MD&A

Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.